Pfizer CEO says 'all in' on experimental weight-loss drug
Posted: Tue Feb 11, 2025 4:23 am
When Trump was running for president, he proposed imposing tariffs on all imported goods. After winning the election in November, he proposed in early December to impose a 25% tariff on imports from Canada and Mexico first.
4. Eli Lilly expects Q4 revenue to be lower than previous guidance and below market expectations
1.14 Eli Lilly and Company announced that it expects revenue in the fourth quarter of 2024 to reach approximately US$13.5 billion, approximately US$400 million less than the lower end of the company's chinese malaysia data recently released forecast range. Analysts expected US$13.93 billion. The company expects full-year revenue of about $45 billion in 2024, $4 billion higher than the midpoint of its previous forecast range. Analysts expected $45.47 billion. In addition, Eli Lilly expects revenue to be between $58 billion and $61 billion in 2025, while analysts expect $58.44 billion.
The company said that the sales trend of Mounjaro and Zepbound is positive, the supply of GLP-1 drugs will increase by more than 60% in the first half of 2025, and a number of new drugs will be launched to boost performance growth. Revenue growth in 2025 is expected to come from new drugs.
1.14 Albert Bourla, CEO of US drugmaker Pfizer, said at the JPMorgan Healthcare Conference on Monday that the company is "going all out" on developing its experimental weight loss drug and has been recruiting more experts in the field. Bourla said these experts are helping Pfizer make better, more rational decisions, and the company may start a late-stage study of its GLP-1R small-molecule agonist danuglipron in the second half of this year.
After extensive experiments, Pfizer expects to have data from the dose-testing study within a few months. With the drug, Pfizer aims to offer patients a more convenient, oral alternative to injections - two drugs that currently dominate the market for weight loss treatments.
4. Eli Lilly expects Q4 revenue to be lower than previous guidance and below market expectations
1.14 Eli Lilly and Company announced that it expects revenue in the fourth quarter of 2024 to reach approximately US$13.5 billion, approximately US$400 million less than the lower end of the company's chinese malaysia data recently released forecast range. Analysts expected US$13.93 billion. The company expects full-year revenue of about $45 billion in 2024, $4 billion higher than the midpoint of its previous forecast range. Analysts expected $45.47 billion. In addition, Eli Lilly expects revenue to be between $58 billion and $61 billion in 2025, while analysts expect $58.44 billion.
The company said that the sales trend of Mounjaro and Zepbound is positive, the supply of GLP-1 drugs will increase by more than 60% in the first half of 2025, and a number of new drugs will be launched to boost performance growth. Revenue growth in 2025 is expected to come from new drugs.
1.14 Albert Bourla, CEO of US drugmaker Pfizer, said at the JPMorgan Healthcare Conference on Monday that the company is "going all out" on developing its experimental weight loss drug and has been recruiting more experts in the field. Bourla said these experts are helping Pfizer make better, more rational decisions, and the company may start a late-stage study of its GLP-1R small-molecule agonist danuglipron in the second half of this year.
After extensive experiments, Pfizer expects to have data from the dose-testing study within a few months. With the drug, Pfizer aims to offer patients a more convenient, oral alternative to injections - two drugs that currently dominate the market for weight loss treatments.